Swiss health care company Roche has launched the new global cancer immunotherapy Centers of Research Excellence (imCORE) Network and plans to invest up to CHF100m ($100m) in the project.

The network brings together global scientific and clinical experts in cancer immunotherapy to collaborate in investigating new treatment approaches.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The launch of imCORE is aimed at initiating pre-clinical and clinical research based on the latest scientific discoveries in addition to sharing data to accelerate the search for cancer cure.

As part of the project, new approaches would be identified to expand the number of people who benefit from cancer immunotherapy.

"The research network comprises 21 academic centres across the globe and is intended to support basic and clinical research collaboration to advance the science of cancer immunotherapy."

Roche global product development chief medical officer and head Sandra Horning said: “We believe the fastest way to advance progress against cancer is through collaboration, and consistent with our values, the goal of imCORE is to facilitate access to new technologies and emerging data among the top researchers around the world.

“imCORE represents our most recent commitment to collaborate with the global cancer community to further understand the biology and immunology of cancer, and to develop new treatments that may one day offer a cure for people with cancer.’’

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The research network comprises 21 academic centres across the globe and is intended to support basic and clinical research collaboration to advance the science of cancer immunotherapy.

Scientists from these centres will work with scientists from Roche and Genentech, a member of the Roche group in the US to develop potential cures for people with cancer.

Roche is also collaborating with the network on existing and new investigational medicines, diagnostic technologies and emerging data.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact